Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 6Neuroblastoma 5Central Nervous System Neoplasms 5Gliosarcoma 4Medulloblastoma 3Glioma 3Brain Neoplasms 3Sarcoma 2Rhabdoid Tumor 2Recurrence 2Pinealoma 2Ependymoma 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Osteosarcoma 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Lymphoma 1Leukemia 1Histiocytosis, Langerhans-Cell 1Carcinoma 1Brainstem Glioma 1Astrocytoma 1

Interventions

mirdametinib 2tipifarnib 1talimogene laherparepvec 1peginterferon alfa-2b 1nilotinib 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Temozolomide 1Talaporfin 1Sirolimus 1Restraint, Physical 1Ranibizumab 1Radiosurgery 1Photochemotherapy 1Neurofibromin 1 1Mn-PyC3A 1Imatinib Mesylate 1Everolimus 1Elasticity Imaging Techniques 1Deoxycholic Acid 1Cryotherapy 1Celecoxib 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma × Celecoxib × CNS × Clear all
NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Corewell Health West

Phase 2 Completed
9 enrolled 9 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡